Novartis shells out $200M-plus for Spinifex and its mid-stage pain drug

Novartis ($NVS) snapped up tiny Spinifex and its mid-stage pain drug in a $200 million-plus deal. The Swiss drugmaker isn't saying much about the deal--it won't discuss the potential milestone payments that are part of the deal--but does say it plans to hustle the drug into a Phase IIb study for either diabetic neuropathy or postherpetic neuralgia, otherwise known as shingles pain. More from FierceBiotech

Suggested Articles

In previously untreated nonsquamous NSCLC, a Tyvyt-chemo combo beat chemo alone at stalling the time to tumor progression or death.

Roche’s Tecentriq didn't repeat its prior TNBC success when tested in tandem with chemo med paclitaxel in previously untreated metastatic patients.

Alexion Pharmaceuticals names its first chief diversity officer as the rare disease specialist looks to cultivate diversity and inclusion.